TY - JOUR
T1 - Circulating micrornas
T2 - Next-generation cancer detection
AU - Matsuzaki, Juntaro
AU - Ochiya, Takahiro
N1 - Funding Information:
In 2014, a large-scale national project in Japan—Development and Diagnostic Technology for Detection of miRNA in Body Fluids—was launched; it was supported by the New Energy and Industrial Technology Development Organization and the Japan Agency for Medical Research and Development. This project aimed to facilitate early detection of 13 types of malignant diseases— breast, lung, gastric, colorectal, esophagus, liver, pancreatic, biliary tract, prostate, bladder, and ovarian cancers; sarcomas; and gliomas—using serum miRNAs. Through this project, we accumulated evidence regarding the utility of serum miRNA testing (Fig. 3). Although not all the achievements of the project have yet been published, we present here a short summary of some of the published results.
Publisher Copyright:
© 2020 by The Keio Journal of Medicine.
PY - 2020/12
Y1 - 2020/12
N2 - Early detection of cancer is crucial for its ultimate control and the prevention of malignant progression. In Japan, a nationwide project was conducted between 2014 and 2019 to develop novel cancer detection tools using serum microRNAs (miRNAs). Using the National Cancer Center Biobank, we collected more than 10,000 serum samples from patients with malignant diseases, including rare cancers such as ovarian cancer, gliomas, and sarcomas. Subsequently, comprehensive miRNA microarray analyses were performed for all samples. This serum miRNA database provides insights regarding miRNA bio-marker candidates for each cancer type. Here, we summarize the major achievements of this national project. Notably, although circulating miRNAs packaged in extracellular vesicles are thought to be a cell-to-cell communication tool, the functional characteristics of the miRNAs listed in the project are still unknown. We hope that our findings will help elucidate the biological functions of circulating miR-NAs.
AB - Early detection of cancer is crucial for its ultimate control and the prevention of malignant progression. In Japan, a nationwide project was conducted between 2014 and 2019 to develop novel cancer detection tools using serum microRNAs (miRNAs). Using the National Cancer Center Biobank, we collected more than 10,000 serum samples from patients with malignant diseases, including rare cancers such as ovarian cancer, gliomas, and sarcomas. Subsequently, comprehensive miRNA microarray analyses were performed for all samples. This serum miRNA database provides insights regarding miRNA bio-marker candidates for each cancer type. Here, we summarize the major achievements of this national project. Notably, although circulating miRNAs packaged in extracellular vesicles are thought to be a cell-to-cell communication tool, the functional characteristics of the miRNAs listed in the project are still unknown. We hope that our findings will help elucidate the biological functions of circulating miR-NAs.
KW - Biomarker
KW - Cancer
KW - Extracellular vesicle
KW - MiRNA
KW - Serum
UR - http://www.scopus.com/inward/record.url?scp=85098707268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098707268&partnerID=8YFLogxK
U2 - 10.2302/kjm.2019-0011-OA
DO - 10.2302/kjm.2019-0011-OA
M3 - Review article
C2 - 32404538
AN - SCOPUS:85098707268
SN - 0022-9717
VL - 69
SP - 88
EP - 96
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
IS - 4
ER -
